Cencora Q4 2022 Earnings Report
Key Takeaways
AmerisourceBergen Corporation reported a 3.8% increase in revenue for the fourth quarter of fiscal year 2022, reaching $61.2 billion. GAAP diluted EPS was $1.40, while adjusted diluted EPS increased by 8.8% to $2.60. The company's performance was driven by growth in U.S. Healthcare Solutions, offset by a decrease in International Healthcare Solutions due to foreign currency translation.
Revenue increased by 3.8% to $61.2 billion in the fourth quarter of fiscal 2022.
GAAP diluted EPS was $1.40 for the quarter.
Adjusted diluted EPS increased by 8.8% to $2.60 in the fiscal fourth quarter.
U.S. Healthcare Solutions revenue increased by 4.7%, while International Healthcare Solutions revenue decreased by 2.7%.
Cencora
Cencora
Forward Guidance
AmerisourceBergen introduced its fiscal year 2023 financial guidance, expecting revenue growth in the range of 5 to 7 percent and adjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent.
Positive Outlook
- Revenue growth to be in the range of 5 to 7 percent.
- On a constant currency basis, revenue growth to be in the range of 6 to 8 percent.
- U.S. Healthcare Solutions revenue growth to be in the range of 6 to 8 percent.
- Adjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent.
- Adjusted free cash flow to be approximately $2 billion.
Challenges Ahead
- International Healthcare Solutions revenue decline to be in the range of 1 to 5 percent.
- Adjusted operating income growth to be in the range of 0 to 3 percent.
- International Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent.
- Excluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating income decline to be in the range of 7 to 11 percent.
- Adjusted effective tax rate to be approximately 20 percent to 21 percent.